Always Remember - Buy The Dip

Sentiment Analysis For VTAE

The news is currently generally neutral for VTAE.

Based on TextBlob analysis of Yahoo! Finance news summaries for VTAE on 2015-09-01.

Yahoo! Finance News for VTAE

Vitae Pharma: Boehringer To End License Agreement For BACE Inhibitors
Vitae Pharma: Boehringer To End License Agreement For BACE Inhibitors

Vitae Pharmaceuticals (VTAE) Falls: Stock Tumbles 9.6% - Tale of the Tape
Vitae Pharmaceuticals, Inc.(VTAE) saw a big move in the last trading session, as the company's shares fell by nearly 10% on the day. The move came on pretty good volume too with far more shares changing hands than in

Earnings Estimates Moving Higher for Vitae (VTAE): Time to Buy? - Tale of the Tape
Vitae Pharmaceuticals, Inc. ( VTAE ) is a stock in the Medical Drugs space that could be an interesting play for investors. That is because, not only does the stock have decent short term momentum, but it is seeing

Vitae Pharmaceuticals (VTAE) Shares March Higher, Can It Continue? - Tale of the Tape
As of late, it has definitely been a great time to be an investor in Vitae Pharmaceuticals Inc ( VTAE ) . The stock has moved higher by 5% in the past month, while it is also above its

Health Care Sector Update for 01/20/2015: VTAE,PETS,MDWD
Top Health Care Stocks JNJ 3.25% PZE +0.73% MRK 1.21% ABT 0.88% AMGN 0.79% Health care stocks were moderately lower today with the NYSE Health Care Sector Index dropping 0.5% and shares of health care companies in the S&P

TPG-backed biotech Virobay withdraws $50 million IPO
Virobay, an early stage biotech with a drug platform for pain and autoimmune diseases, withdrew its plans for an initial public offering on Friday. The company originally planned to raise $50 million during the week of October 13. Virobay'sdrug

Sector Update: Health Care
Health care stocks were broadly higher today with the NYSE Health Care Sector Index advancing about 0.8% and shares of health care companies in the S&P 500 also posting an 0.8% gain as a group. In company news, Vitae

Sector Update: Health Care Stocks Holding Near Session Highs; Vitae Drug Candidate Reduces Alzheimer's Biomarker by 80%
Top Healthcare Stocks JNJ +0.05% PFE +1.60% ABT 0.57% MRK +0.70% AMGN 1.13% Health care stocks were broadly higher today with the NYSE Health Care Sector Index advancing about 0.8% and shares of health care companies in the S&P

Enbrel biosimilar biotech Coherus BioSciences sets terms for $85 million IPO
Coherus BioSciences, which is developing a biosimilar version of Amgen's Enbrel treatment for inflammatory diseases, announced terms for its IPO on Friday. The Redwood City, CA based company plans to raise $85 million by offering 6.3 million shares at

Another skin biotech: Coherus BioSciences files for a $86 million IPO
Coherus BioSciences, which is developing a biosimilar version of Amgen's Enbrel treatment for inflammatory diseases, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The Redwood City, CA based company, which

TPG-backed biotech Virobay sets terms for $50 million IPO
Virobay, an early stage biotech developing a drug platform for pain, Crohn's disease and psoriasis, announced terms for its IPO on Monday. The Menlo Park, CA based company plans to raise $50 million by offering 3.8 million shares at

Vitae Pharmaceuticals prices IPO at $8, well below the range; slashes valuation by 27%
Vitae Pharmaceuticals, which is developing small molecule drugs for type 2 diabetes and Alzheimer's, raised $55 million by offering 6.9 million shares at $8, well below its $11 $13 price range. The Fort Washington, PA based company had initially